Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Check-CapFRA:7CC -5.77%35 EV-to-EBIT is 2.73 as of Aug. 15, 2026. GuruFocus rates FRA:7CC with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 105 Medical Diagnostics & Research companies, Check-Cap ranks better than 94.29% on this metric.
The historical rank and industry rank for Check-Cap's EV-to-EBIT or its related term are showing as below:
FRA:7CC'
s EV-to-EBIT Range Over the Past 10 Years
Min: 0 Med: 0 Max: 2.68
Current: 2.68
During the past 13 years, the highest EV-to-EBIT of Check-Cap was 2.68. The lowest was 0.00. And the median was 0.00.
FRA:7CC's EV-to-EBIT is ranked better than 94.29% of 105
companies
in the Medical Diagnostics & Research industry
Industry Median: 24.29
vs FRA:7CC: 2.68
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Check-Cap's Enterprise Value for the quarter that ended in Dec. 2025 was €9.52 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Check-Cap's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €3.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Check-Cap EV-to-EBIT Related Terms
Check-Cap EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Check-Cap's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7CC vs XWEL, NDRA, BIAF: EV-to-EBIT Comparison
For the Diagnostics & Research subindustry, Check-Cap's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Check-Cap EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Check-Cap's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Check-Cap's EV-to-EBIT falls into.
Check-Cap's current Enterprise Value is €10.03 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Check-Cap's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €3.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Check-Cap (FRA:7CC) has a EV-to-EBIT of 2.73 as of Aug. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Check-Cap and its competitors. According to the industry distribution chart, Check-Cap ranks #6 out of 105 companies in the Medical Diagnostics & Research industry, placing it in the top 5.7%.
Is Check-Cap's EV-to-EBIT too high?
Check-Cap's current EV-to-EBIT is 2.73. The Medical Diagnostics & Research industry median EV-to-EBIT is 24.29. Check-Cap's value of 2.73 is 88.8% below this industry median. Based on the distribution chart, Check-Cap ranks #6 out of 105 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Check-Cap has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Check-Cap's EV-to-EBIT compare to XWEL and NDRA?
According to the Medical Diagnostics & Research industry distribution chart, Check-Cap ranks #6 out of 105 companies for EV-to-EBIT. This places Check-Cap in the top 6% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 24.29. Check-Cap's value of 2.73 is 88.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 24.29, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Check-Cap's current EV-to-EBIT of 2.73 is 88.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Check-Cap and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 24.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Check-Cap's current EV-to-EBIT is 2.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Check-Cap stock overvalued right now?
Check-Cap (FRA:7CC) has a current EV-to-EBIT of 2.73. The current EV-to-EBIT is 2.73 and 88.8% below the Medical Diagnostics & Research industry median of 24.29. Check-Cap's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Check-Cap (FRA:7CC), the current EV-to-EBIT is 2.73 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.
35GF Score
Get the complete analysis for FRA:7CC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7CC has been successfully added to your 
